Influenza Vaccine Manufacturers’ Panel Discussion

Litjen (L.J) Tan
Chief Policy and Partnerships Officer, Immunize.org
Co-Chair, NAIIS

Estimated Supply for the 2023-2024 Season

• Influenza vaccine supply has not been a challenge for many years.
• All manufacturers have reported that they are on track for the season in terms of vaccine production and are not anticipating any challenges.
  – Vaccine is expected to be available as the FDA releases lots.
• Total number of doses anticipated for the United States for 2023-2024 influenza season = >166.5 million doses
• Last season, manufacturers brought >183 million doses to the market
  – 173 million doses distributed by March 4th, 2022
Historical Medical/Retail Claims by Week
Retail Week Ending March 31, 2023\(^1\)
Medical Week Ending April 1, 2023\(^1\)

- Flu seasons run for 35 weeks Aug to Mar
- Week 1 represents: Aug 09, 2019; Aug 08, 2020; Aug 07, 2021; Aug 06, 2022

\(^1\) Data only reflects active Flu season, Season to Date (August – March); Medical claims are a week behind Retail claims therefore Retail claim week ending dates are adjusted to be consistent with Medical claims

Overall Flu Claims Showed 6% Decline in 2022 vs. 2021, driven primarily by Lower Immunizations in 0-17 Age Cohort

- IQVIA claims:
  - Represents 92% of the retail market and 65% of the medical market. But an adjustment has been made to show ~100%
  - Does not capture CDC, hospital, VA, Military, FQHC, LTC and Cash

<table>
<thead>
<tr>
<th>Private Med</th>
<th>Public Med*</th>
<th>Retail</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>50%</td>
<td>24%</td>
</tr>
<tr>
<td>2021</td>
<td>45%</td>
<td>24%</td>
</tr>
<tr>
<td>2022</td>
<td>42%</td>
<td>25%</td>
</tr>
</tbody>
</table>

*Public Med includes CDC, VA and Military shipments. Assumptions made for competition
65+ Population is growing each year, but overall immunizations remain the same resulting in lower actual VCR each year.

Flu Discussion Topics

• What did we learn from last year (2022-23)?

• What do we foresee for this coming season (2023-24)?

• What can we do to positively impact this season (2023-24)?
As of the end of April, there have been 28,845 reported cases of flu, representing a 347% increase over the prior season.

As of March 8th, there had been 9,695 notifications of influenza this year – with more than 3000 of those cases in children under 14.

Those aged five to nine were most likely to be hospitalized, making up 2,154 admissions per 100,000 members of the population, followed by children under five who made up 1,859.

Flu-nearly disappeared during the pandemic in Australia. Now, cases are soaring!

Similarly, New Zealand is bracing for an early and severe flu season with over 1,240 cases reported as of April 23rd.
Vaccination Formulation/Administration Options May Increase Vaccination Coverage

2041 adults and 4673 parents were surveyed to determine if offering different influenza vaccine formulations would have an impact in influenza vaccine uptake/acceptance.

When offered vaccination options:

- Parents were 5% more likely to vaccinate their children and
- Adults were 5% more likely to get vaccinated themselves

---

Percent among the unvaccinated likely to get vaccinated against influenza*

<table>
<thead>
<tr>
<th>Children, age 2–17 years</th>
<th>Adults, age 18–49 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without options available</td>
<td>Without options available</td>
</tr>
<tr>
<td>44%</td>
<td>39%</td>
</tr>
<tr>
<td>With options available</td>
<td>With options available</td>
</tr>
<tr>
<td>49%</td>
<td>44%</td>
</tr>
</tbody>
</table>

~2.3 million US children
~4.9 million US adults

---

Among the unvaccinated, optionality significantly increases the likelihood to vaccinate against influenza

---

*Anticipated likelihood projected based on Clancy-scale calibrated response among those not already vaccinated (mean).